<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371718</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Thromboembolic Disease and COVID-19: Experience of a University and Emergency Hospital During the Pandemic.</ArticleTitle><Pagination><StartPage>e68767</StartPage><MedlinePgn>e68767</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68767</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68767</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 leads to vasculopathy, which is linked to both a prothrombotic state and an impaired immune response. A notable increase in pulmonary embolism (PE) and deep venous thrombosis (DVT) has been documented.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective analysis of all patients who were admitted with venous thromboembolic disease (VTD) in the largest university and emergency hospital in Romania, between May 1, 2020, and April 30, 2021. Patients were categorized into two groups based on the presence (Group 1) or absence (Group 2) of COVID-19 virus infection at the time of admission. The aim of this study was to assess the characteristics of VTD in COVID-19 patients and to compare the clinical and paraclinical parameters of the Group 1 and Group 2 patients admitted for VTD in an emergency hospital during the first two waves of the pandemic (12 months). We compared clinical, biological, and imaging parameters and applied binary logistic analysis for the predictive models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 198 patients were diagnosed with VTD (at admission or during the hospitalization); out of 33,373 patients hospitalized, 43 (21.7%) were diagnosed with COVID-19 (12.2% with mild COVID-19, 61.0% moderate, and 26.8% severe). Group 1 showed higher heart rates and leukocytes, more severe pulmonary changes (p&lt;0.05), higher N-terminal-pro-B-type natriuretic peptide (NTproBNP), and high sensitivity troponin I (hs-cTnI) (p&gt;0.05). Not reaching statistical significance, the mortality tended to be higher in Group 1. These patients were admitted to the intensive care units for longer (3.5 vs. 1.5 days, p &gt; 0.05). The minimum value of thrombocytes during hospitalization was inversely correlated with the risk of death. Interestingly, the Pulmonary Embolism Severity Index (PESI) score was not predictive for in-hospital death in Group 1, but only in Group 2 (area under the curve (AUC) = 0.821, CI 0.689-0.952).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Individuals with severe manifestations of COVID-19 remain vulnerable to developing VTD and are prone to adverse outcomes. The efficacy of PESI as a predictive tool for in-hospital death is non-significant. Further refinement of specific predictive scores tailored to VTD associated with COVID-19 is needed.</AbstractText><CopyrightInformation>Copyright © 2024, Stefan et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stefan</LastName><ForeName>Miruna F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, University and Emergency Hospital Bucharest, Bucharest, ROU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magda</LastName><ForeName>Lucia S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, University and Emergency Hospital Bucharest, Bucharest, ROU.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rimbas</LastName><ForeName>Roxana C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, University and Emergency Hospital Bucharest, Bucharest, ROU.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinereanu</LastName><ForeName>Dragos</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, University and Emergency Hospital Bucharest, Bucharest, ROU.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology and Cardiovascular Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">emergency hospital</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword><Keyword MajorTopicYN="N">venous thromboembolic disease</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. The ethics committee of the University and Emergency Hospital Bucharest issued approval (37003). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371718</ArticleId><ArticleId IdType="pmc">PMC11456164</ArticleId><ArticleId IdType="doi">10.7759/cureus.68767</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 dashboard.  [
May;
2024 
]. 2024. https://data.who.int/dashboards/covid19/cases https://data.who.int/dashboards/covid19/cases</Citation></Reference><Reference><Citation>The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Bahraini M, Dorgalaleh A. Semin Thromb Hemost. 2022;48:19–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34695858</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. García-Ortega A, Oscullo G, Calvillo P, et al. J Infect. 2021;82:261–269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834386</ArticleId><ArticleId IdType="pubmed">33440207</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Tan BK, Mainbourg S, Friggeri A, et al. Thorax. 2021;76:970–979.</Citation><ArticleIdList><ArticleId IdType="pubmed">33622981</ArticleId></ArticleIdList></Reference><Reference><Citation>Integrating cardiac biomarkers and electrocardiogram in pulmonary embolism prognosis. Borkowski P, Singh N, Borkowska N, Mangeshkar S, Nazarenko N. Cureus. 2024;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10911475</ArticleId><ArticleId IdType="pubmed">38440014</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. EClinicalMedicine. 2020;29:100639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679115</ArticleId><ArticleId IdType="pubmed">33251499</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon? Pavoni V, Gianesello L, Horton A. J Thromb Thrombolysis. 2021;52:542–552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8109223</ArticleId><ArticleId IdType="pubmed">33973157</ArticleId></ArticleIdList></Reference><Reference><Citation>2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Konstantinides SV, Meyer G, Becattini C, et al. Eur Respir J. 2019;54:1901647.</Citation><ArticleIdList><ArticleId IdType="pubmed">31473594</ArticleId></ArticleIdList></Reference><Reference><Citation>Balli S, Shumway KR, Sharan S. StatPearls. Published Online First: 4 September. Treasure Island, FL: StatPearls [Internet], StatPearls Publishing; 2024. Physiology, Fever.</Citation><ArticleIdList><ArticleId IdType="pubmed">32966005</ArticleId></ArticleIdList></Reference><Reference><Citation>Current cigarette smoking among adults in the United States.  [
Aug;
2024 
]. 2023. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm</Citation></Reference><Reference><Citation>COVID-19-associated endothelial dysfunction and microvascular injury: from pathophysiology to clinical manifestations. Canale MP, Menghini R, Martelli E, Federici M. Card Electrophysiol Clin. 2022;14:21–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556628</ArticleId><ArticleId IdType="pubmed">35221082</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaging approach to COVID-19 associated pulmonary embolism. Trunz LM, Lee P, Lange SM, et al. Int J Clin Pract. 2021;75:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237008</ArticleId><ArticleId IdType="pubmed">33966326</ArticleId></ArticleIdList></Reference><Reference><Citation>American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Cuker A, Tseng EK, Nieuwlaat R, et al. Blood Adv. 2021;5:872–888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869684</ArticleId><ArticleId IdType="pubmed">33560401</ArticleId></ArticleIdList></Reference><Reference><Citation>Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Lodigiani C, Iapichino G, Carenzo L, et al. Thromb Res. 2020;191:9–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177070</ArticleId><ArticleId IdType="pubmed">32353746</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic oral anticoagulation and clinical outcome in hospitalized COVID-19 patients. Russo V, Bottino R, D'Andrea A, et al. Cardiovasc Drugs Ther. 2022;36:705–712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8120255</ArticleId><ArticleId IdType="pubmed">33988835</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the emergency department: results of the UMC-19-S8. Jiménez S, Miró Ò, Llorens P, et al. Eur J Emerg Med. 2021;28:218–226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082992</ArticleId><ArticleId IdType="pubmed">33904528</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics of coronavirus disease 2019 in China. Guan WJ, Ni ZY, Hu Y, et al. N Engl J Med. 2020;382:1708–1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region. Arribalzaga K, Martínez-Alfonzo I, Díaz-Aizpún C, et al. Thromb Res. 2021;203:93–100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8106233</ArticleId><ArticleId IdType="pubmed">33989984</ArticleId></ArticleIdList></Reference><Reference><Citation>D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Garcia-Olivé I, Sintes H, Radua J, Abad Capa J, Rosell A. Respir Med. 2020;169:106023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219417</ArticleId><ArticleId IdType="pubmed">32454268</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromboembolic risk in COVID-19 patients: is there a hidden link? Cidade J, Pinheiro H, Dias A, et al. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8596081</ArticleId><ArticleId IdType="pubmed">34804704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Scudiero F, Silverio A, Di Maio M, et al. Thromb Res. 2021;198:34–39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7669475</ArticleId><ArticleId IdType="pubmed">33271421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>